Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of 2 NovoFine® Needles on the Reflux of Insulin
Phase 3
Completed
- Conditions
- First Posted Date
- 2009-03-31
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00872560
- Locations
- 🇮🇹
Novo Nordisk Investigational Site, Chieti, Italy
Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles
Phase 3
Completed
- Conditions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT00871416
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Århus, Denmark
Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66726
- Registration Number
- NCT00869908
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1032
- Registration Number
- NCT00865397
- Locations
- 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 987
- Registration Number
- NCT00856986
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom
Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 139
- Registration Number
- NCT00853086
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 84
- Registration Number
- NCT00851773
Observational Study on Levemir® in Obese Diabetic Patients
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 580
- Registration Number
- NCT00849342
Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT00849316
Safety of NovoMix® 30 or Levemir® for Treatment of Type 2 Diabetics in Macedonia
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3421
- Registration Number
- NCT00842894
© Copyright 2024. All Rights Reserved by MedPath